News zum Sektor Gesundheit aus Frankreich

 

Ipsen announces the launch of an employee shareholding plan...

ABIVAX: Nombre d'actions composant le capital social et nombre total de droits de vote au 30.04.26...

Sanofi secures FDA priority review for venglustat in GD3, setting up a November decision on a potential first U.S. therapy for neurological symptoms....

If approved, venglustat would be the first treatment in the US to address the neurological symptoms of GD3, which currently have no targeted therapies. The decision is anticipated The post FDA grants priority review for Sanofi's venglustat NDA appeared first on Pharmaceutical Business review....

France To Reimburse Patients For Anti-Obesity Drugs Authored by Guy Birchall via The Epoch Times, France is set to begin reimbursing severely obese people for the cost of weight-loss drugs, French Health Minister Stéphanie Rist said on May 28. Wegovy at a pharmacy in London on March 8, 2024. Hollie Adams/Reuters She said that Paris would subsidize the use of Danish company Novo Nordisk's Wegovy and American pharma giant Eli Lilly's Mounjaro from mid-June. "I am quite proud, because we are the first country in the European Union to provide reimbursement ... on a permanent basis," Rist told French broadcaster TFI. Officially, reimbursement will cover 65 percent of the cost of the weight-loss drugs, "but almost all patients will be covered" in full if they have "comorbidities, such as high blood pressure or diabetes," she said. "For the vast majority, it will be 100 percent reimbursement," Rist added. She said the eligibility criteria for the scheme woul...

Paris (www.aktiencheck.de) - Charles-River-Laboratories-Chartanalyse der BNP Paribas: Rückblick: Mit einem Kurssprung von über 10% hat die Charles-River-Laboratories-Aktie (ISIN: US1598641074, WKN: 939391, Ticker-Symbol: RV6, NYSE-Symbol: CRL) am Vortag sämtliche gleitenden Durchschnitte und die Ichimoku-Wolke in einem Zug überwunden und schloss bei 181,34 USD, wie aus der Veröffentlichung "dailyAKTIEN" der BNP Paribas hervorgeht. [mehr]...

OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing...

Does Abivax SA Sponsored ADR (ABVX) have what it takes to be a top stock pick for momentum investors? Let's find out....

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced the hosting of live videoconference on Tuesday, June 16, 2026, to present its financial results for the fiscal year ending March 31, 2026. The results will be published earlier that day following the closing of the Paris stock exchange. The presentation will be conducted simultaneously in English and French to accommodate a broad audience of investors, analysts, and stakeholders. Videoconference in English, 6:00pm CEST / 12:00pm ET >https://www.medincell.com/annual-results-2025-2026-register/ During the videoconference, Medincell's management team will provide an overview of the company's performance and strategic outlook, followed by a Q&A session in English. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments ac...

Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026....

FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Sanofi mit einem Kursziel von 100 Euro auf "Buy" belassen. In den Gesprächen mit den Franzosen sei es vor allem um den Umbruch in der Führung gegangen, schrieb Emmanuel Papadakis ......

PARIS (dpa-AFX) - Sanofi SA (SNY) on Thursday said the US Food and Drug Administration (FDA) has granted priority review to the new drug application for venglustat for the treatment of type 3 Gauc......

PARIS, FRANCE, 28 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of new late-breaking results from the ELATIVE® Phase III trial and two real-world studies at the European Association for the Study of the Liver (EASL) congress. Together, these data further strengthen the growing body of evidence establishing IQIRVO® as the only second-line primary biliary cholangitis (PBC) treatment providing rapid and robust alkaline phosphatase (ALP) reduction with fatigue improvement (in patients with moderate-to-severe fatigue at baseline) and pruritus relief....

Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease...

Aggregated presentation by day and by market...

VALBIOTIS SA: Monacolins from Red Yeast Rice: On May 13, EU Member States voted in favor of the draft regulation aimed at banning monacolins from red yeast rice...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Size of the Fully Guaranteed Capital Increase with subscription rights: EUR 32.7m Subscription ratio: 1 new share for every 5 existing shares Subscription price: 2.65 euro per new share Subscription Rights Trading Period: from May 29 to June 11, 2026 included Theorical value of subscription right: 0.1375 euro Subscription Period: from June 2 to June 15, 2026 included Firm commitment from Fenja Capital, a Scandinavian fund acting as the Company's new lead investor - investing outside its region for the first time - for EUR 10m in a non-dilutive loan, which may be increased to EUR 14m, and EUR 4m guarantee in the capital increase Net proceeds dedicated to Phase 2b clinical trial in sepsis and to Marketing Authorization Application (MAA) in LCAT Deficiency TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) (“Abionyx” or the “Company”), a next-generation biopharmaceutical company developing innovative therapies in se...

Share capital increase without shareholders' preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros. A share capital increase without shareholders' preferential subscription rights reserved for the Guarantors (as defined below) for a maximum amount of 10 million euros, should all the ordinary shares issued in the framework of the public offering be fully subscribed; Firm subscription and backstop commitments for a total amount of 30 million euros, including 20 million euros under the subscription commitments, representing total commitments equal to 75% of the public offering; Subscription price: 5.00 euros per ordinary share; and The net proceeds of the share capital increase will be allocated to the commercial launch of eyonis® LCS in the United States and Europe, and to the financing of the extension of the eyonis® medical device software suite for the early diagnosis of cancers ...

PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the “Closing”) of its global offering (the “Global Offering”), including in respect of the earlier total exercise by the underwriters of their option (the “Option”) to purchase additional new ordinary shares in the form of additional American Depositary Shares (the “Additional ADSs”)....